Nizatidine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→‎Clinical use: fix wikilink
No edit summary
Line 55: Line 55:
| StdInChIKey = SGXXNSQHWDMGGP-IZZDOVSWSA-N
| StdInChIKey = SGXXNSQHWDMGGP-IZZDOVSWSA-N
}}
}}
'''Nizatidine''' is a histamine [[H2-receptor antagonist|H<sub>2</sub>-receptor antagonist]] that inhibits [[gastric acid|stomach acid]] production, and commonly used in the treatment of [[peptic ulcer]] disease (PUD) and [[gastroesophageal reflux]] disease (GERD). It was developed by [[Eli Lilly and Company|Eli Lilly]] and is marketed under the brand names '''Tazac''' and '''Axid'''.
'''Nizatidine''' is a histamine [[H2-receptor antagonist|H<sub>2</sub>-receptor antagonist]] that inhibits [[gastric acid|stomach acid]] production, and is commonly used in the treatment of [[peptic ulcer]] disease and [[gastroesophageal reflux]] disease. It was developed by [[Eli Lilly and Company|Eli Lilly]] and is marketed under the brand names Tazac and Axid.


==Clinical use==
==Clinical use==
{{main|H2-receptor antagonist}}
{{main|H2-receptor antagonist}}
Nizatidine is used to treat [[duodenal ulcers]], [[gastric ulcers]], [[gastroesophageal reflux disease]], and to prevent [[stress ulcer]]s.<ref name=LiverTox/>
Nizatidine is used to treat [[duodenal ulcers]], [[gastric ulcers]], and [[gastroesophageal reflux disease]] (GERD), and to prevent [[stress ulcer]]s.<ref name=LiverTox/>


==Adverse effects==
==Adverse effects==
Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache and muscle aches.<ref name=LiverTox/>
Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.<ref name=LiverTox/>


==History and development==
==History and development==
Nizatidine was developed by [[Eli Lilly and Company|Eli Lilly]], and was first marketed in 1987. It is considered to be equipotent with [[ranitidine]] and differs by the substitution of a [[thiazole]]-ring in place of the [[furan]]-ring in ranitidine. In September 2000 Eli Lilly announced they would sell the sales and marketing rights for Axid to [[Reliant Pharmaceuticals]]. <ref name="encyclopedia">[http://www.encyclopedia.com/doc/1G1-65062714.html?Q=%22axid%22 Eli Lilly and Company and Reliant Pharmaceuticals Announce<!-- Bot generated title -->]</ref> Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA). <ref name="reliant2004">[http://www.reliantrx.com/investor/press_releases/072604.htm Reliant Pharmaceuticals : Press Releases<!-- Bot generated title -->]</ref> However, a year later they sold rights of the Axid Oral Solution (including the issued patent [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6930119.PN.&OS=PN/6930119&RS=PN/6930119 US6,930,119] protecting the product) to [[Braintree Laboratories]].<ref name="reliant2005">[http://www.reliantrx.com/investor/press_releases/063005.htm Reliant Pharmaceuticals : Press Releases<!-- Bot generated title -->]</ref>
Nizatidine was developed by [[Eli Lilly and Company|Eli Lilly]], and was first marketed in 1987. It is considered to be equipotent with [[ranitidine]] and differs by the substitution of a [[thiazole]] ring in place of the [[furan]] ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to [[Reliant Pharmaceuticals]]. <ref name="encyclopedia">[http://www.encyclopedia.com/doc/1G1-65062714.html?Q=%22axid%22 Eli Lilly and Company and Reliant Pharmaceuticals Announce<!-- Bot generated title -->]</ref> Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA). <ref name="reliant2004">[http://www.reliantrx.com/investor/press_releases/072604.htm Reliant Pharmaceuticals : Press Releases<!-- Bot generated title -->]</ref> However, a year later, they sold rights of the Axid Oral Solution (including the issued patent [http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6930119.PN.&OS=PN/6930119&RS=PN/6930119 US6,930,119] protecting the product) to [[Braintree Laboratories]].<ref name="reliant2005">[http://www.reliantrx.com/investor/press_releases/063005.htm Reliant Pharmaceuticals : Press Releases<!-- Bot generated title -->]</ref>


Nizatidine proved to be the last new histamine H<sub>2</sub>-receptor antagonist introduced prior to the advent of [[proton pump inhibitor]]s.
Nizatidine proved to be the last new histamine H<sub>2</sub>-receptor antagonist introduced prior to the advent of [[proton pump inhibitor]]s.
==See also==
==See also==
*[[Famotidine]], aka Pepcid AC, Pepcidine: another popular H2-receptor antagonist
*[[Famotidine]], Pepcid AC, Pepcidine: another popular H<sub>2</sub>-receptor antagonist


==References==
==References==

Revision as of 02:48, 18 December 2014

Nizatidine
Clinical data
Trade namesAxid
AHFS/Drugs.comMonograph
MedlinePlusa694030
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: Rx and OTC[1]
Pharmacokinetic data
Bioavailability>70%
Protein binding35%
MetabolismHepatic
Elimination half-life1-2 hours
ExcretionRenal
Identifiers
  • N-(2-[(2-[(dimethylamino)methyl]thiazol-4-yl)methylthio]ethyl)-N-methyl-2-nitroethene-1,1-diamine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.155.683 Edit this at Wikidata
Chemical and physical data
FormulaC12H21N5O2S2
Molar mass331.46 g/mol g·mol−1
3D model (JSmol)
  • [O-][N+](=O)\C=C(/NC)NCCSCc1nc(sc1)CN(C)C
  • InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+ checkY
  • Key:SGXXNSQHWDMGGP-IZZDOVSWSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid.

Clinical use

Main article: H2-receptor antagonist

Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD), and to prevent stress ulcers.[1]

Adverse effects

Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.[1]

History and development

Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals. [2] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA). [3] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent US6,930,119 protecting the product) to Braintree Laboratories.[4]

Nizatidine proved to be the last new histamine H2-receptor antagonist introduced prior to the advent of proton pump inhibitors.

See also

  • Famotidine, Pepcid AC, Pepcidine: another popular H2-receptor antagonist

References

  1. ^ a b c U.S. National Library of Medicine Last updated: 4 November 2014 LiverTox Database: Nizatidine
  2. ^ Eli Lilly and Company and Reliant Pharmaceuticals Announce
  3. ^ Reliant Pharmaceuticals : Press Releases
  4. ^ Reliant Pharmaceuticals : Press Releases

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Nizatidine&oldid=638589053"